Low dose level:0.5×10^6 UCAR+ T Cells/kg
Sponsors
Zhongshan People's Hospital
Conditions
Advanced gliomasAdvanced gynecological tumorMalignant head and neck squamous cell carcinomaR/RMultiple myelomaRelapsed/Refractory Acute Myeloid LeukemiaRelapsed/refractory CD19-positive B-cell malignancies
Early Phase 1
Clinical study on the safety and tolerability of targeting CD33 UCAR-T cell injection in patients with relapsed/refractory acute myeloid leukemia
RecruitingChiCTR2000039293
Start: 2021-01-01Updated: 2021-01-25
To evaluate the safety and tolerability of CD19 UCAR-T cell injection in subjects with recurrent/refractory CD19 positive B cell malignancies
RecruitingChiCTR2000039849
Start: 2021-01-01Updated: 2021-02-22
To evaluate the safety and tolerability of CD19-BCMA UCAR-T cell injection in patients with relapsed or refractory multiple myeloma
RecruitingChiCTR2000039852
Start: 2021-01-01Updated: 2021-02-22
A clinical study to evaluate the safety and tolerability of AMT-116 UCAR-T cell injection in subjects with malignant head and neck squamous cell carcinoma
RecruitingChiCTR2000039850
Start: 2021-01-01Updated: 2021-02-22
Phase 1
Objective to evaluate the safety and efficacy of B7-H3 ucar-t cell injection in the treatment of advanced glioma
RecruitingChiCTR2100042402
Start: 2021-01-21Updated: 2021-04-26
Objective to evaluate the safety and efficacy of IL-13Ra2 ucar-t cell injection in the treatment of advanced glioma
RecruitingChiCTR2100042400
Start: 2021-01-21Updated: 2021-04-26
Objective to evaluate the safety and efficacy of mesothelin ucar-t cell injection in the treatment of advanced gynecological tumors
RecruitingChiCTR2100042392
Start: 2021-01-21Updated: 2021-04-26